glp-1 companion app companies AI accelerates digital health development with Phlo's GLP1 app | Marc Sluijs posted on the topic Maximizing the Promise of Prescriptions:

Ozempic Blindness Lawsuit Overview Ozempic blindness lawsuits claim that the drugs manufacturer, Novo Nordisk, failed to adequately warn consumers about the risk of vision loss caused by non-arteritic anterior ischemic optic neuropathy (NAION)

Viral moments were often sparked by reactions to celebrity transformations, discussions of Ozempic's impact on beauty standards, or commentary on the growing market power of companies such as Novo Nordisk and Eli Lilly

That could tip the scale of any judgment on their ability to enhance performance

MarketScan data shows that only 66% of continuously enrolled new GLP-1 patients were persistent on Obesity medications for at least 40 weeks (10 months) in 2022 2024, compared to 77% of patients taking Diabetes products

This mechanism enhances insulin secretion in response to meals, suppresses glucagon release, slows gastric emptying, and reduces appetitecollectively helping to improve glycaemic control and promote weight loss